Shanghai, Tianjin reported new new crown cases, local employees said "very stable"
Release time:
2020-12-01
Shanghai, Tianjin reported new new crown cases
local employees said "very stable"
This newspaper recently, Shanghai, Tianjin Binhai New Area has reported the discovery of new crown pneumonia confirmed cases, the company in the two places of the three enterprises are in accordance with the relevant requirements of the government to implement prevention and control measures, production and operation order to maintain a good, employee mentality is stable.
11# On July 9 and 19, Shanghai Pudong and Tianjin Binhai New Area reported the discovery of new confirmed cases of new coronary pneumonia, which became the focus of social attention. The relevant situation of Shanghai North Carolina Company, Tianjin Jianfeng Natural Products Company and Tianjin Jianfeng Flanders Company under the Pharmaceutical Company also affected the hearts of colleagues in other regions. It is understood that after the discovery of new cases, Shanghai and Tianjin successively launched investigation and prevention and control measures, the social order of the two places was stable, and the daily operation and management of the company's three subordinate enterprises were not affected. In particular, the two enterprises located in Binhai New Area have carried out nucleic acid testing for all employees according to the unified arrangement of the health and epidemic prevention department, and daily preventive measures such as daily disinfection in the area, temperature testing in and out, and disinfection of incoming materials and packaging have been further strengthened. Kang Litao, general manager of Shanghai North Carolina Company, said that since the outbreak of the new crown epidemic this year, local health and epidemic prevention departments have established a relatively perfect early warning, prevention and control and treatment workflow, the daily prevention and control work of enterprises continues to carry out, employees' awareness of epidemic prevention has been enhanced, and new individual cases will not cause major panic.
Since the beginning of winter, local sporadic cases have occurred in many parts of the country. According to the information provided by the health and epidemic prevention authorities, the new crown virus likes low temperature environment, the lower the temperature, the longer the survival time, with the advent of the season of high incidence of respiratory infectious diseases, cargo transport, like the cold chain, has become the carrier of virus input, coupled with the decline in the vigilance of some people, the risk of the spread of the new crown epidemic increased. Therefore, all units under the company still need to pay close attention to relevant information, improve the vigilance of cold chain food and inbound goods, strengthen the prevention and control of epidemic situation in key places, and earnestly do a good job in the normal prevention and control of the new coronary pneumonia epidemic. Individual employees should also pay full attention to personal protection and health monitoring, do not go to medium and high-risk areas unless necessary, and further enhance personal protection awareness and protection ability. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page